Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin and Oral Semaglutide in MCI and MetS
NCT06072963Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide, Generex Oral-lyn in Mild Cognitive Impairment (MCI), metabolic syndrome, sponsored by Rutgers University. Started Jan 2024; status: recruiting.
02
Drugs
semaglutideGenerex Oral-lyn
03
Conditions
Mild Cognitive Impairment (MCI)metabolic syndrome
Beyond the preview
Go deeper on NCT06072963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072963.